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Abstract 
Aims: Doxorubicin (DOX) is widely used in cytostatic treatments, although it may cause 
cardiovascular dysfunction as a side effect. DOX treatment leads to enhanced free radical 
production that in turn cause DNA strand breakage culminating in poly(ADP-ribose) 
polymerase (PARP) activation, mitochondrial and cellular dysfunction. DNA nicks can 
activate numerous enzymes, such as PARP-2. Depletion of PARP-2 has been shown to result 
in a protective phenotype against free radical-mediated diseases suggesting similar properties 
in the case of DOX-induced vascular damage. 
Methods and Results: PARP-2+/+ and -/- mice and aortic smooth muscle (MOVAS) cells 
were treated with DOX (25 mg/kg, or 3 µM, respectively). Aortae were harvested 2 days post 
treatment. Aortae from PARP-2-/- mice displayed partial protection against DOX toxicity, and 
the protection depended on the conservation of smooth muscle, but not on the conservation of 
endothelial function. DOX treatment evoked free radical production, DNA breakage and 
PARP activation. Importantly, depletion of PARP-2 did not quench any of these phenomena 
suggesting an alternative mechanism. Depletion of PARP-2 prevented DOX-induced 
mitochondrial dysfunction through SIRT1 activation. Genetic deletion of PARP-2 resulted in 
the induction of SIRT1 promoter and consequently increased SIRT1 expression both in aortae 
and in MOVAS cells. SIRT1 activation enhanced mitochondrial biogenesis which provided 
protection against DOX-induced mitochondrial damage. 
Conclusions: Our data identify PARP-2 as a mediator of DOX toxicity by regulating vascular 
SIRT1 activity and mitochondrial biogenesis. Moreover, to our best knowledge this is the first 
report of SIRT1 as a protective factor in the vasculature upon oxidative stress. 
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Introduction 
Doxorubicin (adriamicin, DOX) is a widely used antitumor drug exerting cardiovascular 
side effects that may culminate in irreversible degenerative cardiomyopathy and heart failure 
1
. DOX-induced cardiovascular injury is linked to increased oxidative stress2 as DOX can 
export electrons from the mitochondria via redox cycling creating radical species3.  Although 
cardiac effects of DOX toxicity are well characterized, vascular damage is scarcely mapped 
and the molecular background is largely unknown. Vascular damage upon DOX treatment 
affects the aorta4, 5, and smaller arteries in the liver6 and kidney7, 8. Furthermore, DOX impairs 
endothelial function9 and promotes thrombosis10. 
Free radical evoked DNA damage activates poly(ADP-ribose) polymerase (PARP)-1 that 
catabolizes NAD+ in order to create poly(ADP-ribose) (PAR) polymers. PARP-1 activation 
leads to NAD+ and consequently ATP-depletion provoking cell dysfunction and cell death11. 
This PARP-1-mediated cell death pathway is active in DOX-induced toxicity and it is a major 
contributor to cardiac and vascular dysfunction12, 13. Therefore, pharmacological inhibition of 
PARP-1 proved to be advantageous under such circumstances12, 13. Upon DOX damage PARP 
inhibition partially restored vascular contractility13. 
PARP-2 is a nuclear enzyme that can bind to DNA nicks and thereby become active14. 
Upon activation it is capable of synthesizing PAR at the expense of NAD+14. Moreover, 
PARP-2-/- mice are resistant to numerous oxidative stress-related pathologies in the brain and 
intestines15-17. These properties of PARP-2 prompted us to examine whether PARP-2 
inactivation may also provide protection against DOX-induced vascular damage. 
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Materials and Methods 
 
All chemicals were from Sigma-Aldrich unless stated otherwise. 
 
Animal experiments 
All animal experiments were carried out according to the national and EU ethical guidelines 
and were authorized by the institutional ethical committee (7/2010 DE MÁB). Homozygous 
female PARP-2-/- and littermate PARP-2+/+ mice18 derived from heterozygous crossings were 
kept in a 12/12 h dark-light cycle with ad libitum access to water and food. Mice were 
randomly assigned to 4 groups: PARP-2+/+ and PARP-2-/- control (CTL), and PARP-2+/+ and 
PARP-2-/- DOX treated. DOX treatment was performed by the injection of 25 mg/kg DOX or 
saline i.p. as described 12. Aortae were harvested 2 days post injection for further assessment. 
 
Aorta ring studies 
For aorta ring studies mice were anaesthetized by Thiopental (50 mg/kg, i.v.). Mice 
were dissected after they did not respond to pain. Thoracic aortae were cut to 4 mm rings in 
an organ chamber and were fixed on an isometric contractile force measurement system 
(DMT 510A, Aarhus, Denmark) by metal wires. Aortic rings were stretched according to the 
manufacturer's instructions. Fixed, stretched aortic rings were treated with the indicated 
agents for the indicated times and contractile force was recorded. 
 
Histology and microscopy 
Staining was performed on 7 µm tissue sections or cells using antibodies against PAR, PARP-
2 (both from Alexis, Lausen, Switzerland) and smooth muscle actin (SMA, Novocastra, 
Newcastle upon Tyne , UK) as in 19. 
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TUNEL assay was performed following the instructions of the manufacturer (Millipore). 
 
Cell culture 
MOVAS murine aortic smooth muscle cells were obtained from ATCC and were cultured in 
DMEM (4.5 g/L glucose, 10% FCS, 0.2 mg/mL G418). PARP-2 silencing was performed as 
in 19 employing shPARP-2 (small hairpin) and scPARP-2 (scrambled) shRNA by lentiviral 
delivery. Cellular measurements took place 7 hours after addition of DOX. 
 
Measurement of thiobarbituric acid reactive species (TBARS) 
The extent of oxidative stress was assessed by determining lipid peroxidation. Aortae were 
homogenized in 1.15% KCl. Homoganates were cleared and supernatants were used. 
Supernatants were incubated at 90 oC for 45 mins with thibarbituric acid. After cooling to 
room temperature, absorbance at 532 nm was measured and normalized to protein content. 
The level of lipid peroxides was expressed as percentage of control. 
 
PARP activity measurement 
PARP activity in MOVAS cells was measured by the incorporation of 3H-NAD+. Cells 
stimulated with DOX (3 µM, 7 hours), or H2O2 (1 mM, 10 mins) and were incubated with 3H-
NAD+ (10 min, 37oC). After incubation cellular proteins were precipitated and subsequently 
washed with ice cold TCA (50% w/v and 5% w/v, respectively). Precipitates were solubilized 
in 250 µl 2% w/v SDS/0.1 N NaOH at 37°C overnight. Tritium incorporation was measured 
by liquid scintillation counting. 
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Measurement of superoxide production 
Superoxide was measured using hydroethidine (HE) staining as described in20. Cells were 
induced by DOX (7 hours, 3 µM) and were stained by 2 µM HE for 30 minutes. Fluorescence 
was analyzed by flow cytometry (FACSCalibur, BD Biosciences). Superoxide production was 
indicated as a mean of HE fluorescence in each sample. 
 
Oxygen consumption  
Oxygen consumption was measured using an XF96 oximeter (Seahorse Biosciences, North 
Billerica, MA, USA). scPARP-2 and shPARP-2 MOVAS cells were seeded in 96 well assay 
plates. After recording the baseline oxygen consumption, cells received a single bolus dose of 
DOX (0.3 - 30 µM final concentration). Then oxygen consumption was recorded every 30 
minutes to follow DOX toxicity. Final reading took place at 7 hours post treatment. Oxygen 
consumption rate was normalized to protein content and normalized readings were displayed.  
 
NAD+ measurement 
Cells were seeded in 6-well plates and treated with 3 µM DOX for 7 hours. Control and 
DOX-treated cells were homogenized in 500 µl 0.5 N HClO4 solution and the homogenates 
were then neutralized with 150 µl 3 M KOH. The concentration of NAD+ was measured 
photometrically at 560 nm after enzymatic reaction, which is based on an alcohol 
dehydrogenase cycling reaction in which a tetrazolium dye is reduced by NADH in the 
presence of phenazin methosulphate. Samples were normalized to protein content and NAD+ 
concentration was determined using an NAD+ standard curve. 
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Luciferase activity measurement  
Luciferase activity measurement took place as described in19 with modifications as follows. 
MOVAS cells carrying a stable transfection of a scrambled or specific PARP-2 shRNA were 
seeded in 6-well plates. Transfection took place (8 µg SIRT1 -91 promoter construct21 and 4 
µg β-galactosidase expression plasmid per 9 µl JetPEI transfection reagent (Polyplus 
Transfection, Illkirch, France) after cells reached approximately 60% confluence. Cells were 
scraped 48 hours post transfection and luciferase activity was determined by standard 
procedures. The activity was expressed as luciferase activity/β-galactosidase activity. 
 
Measurement of mitochondrial membrane potential 
Mitochondrial membrane potential was determined by TMRE (tetramethylrhodamine ethyl 
ester) staining22. MOVAS cells carrying a stable transfection of a scrambled or specific 
PARP-2 shRNA were seeded in 96-well plate (25 000 cells/well) and induced by DOX (0.3-
30 µM, 7 hours). After DOX-treatment cells were stained with 100 nM TMRE for 30 minutes 
then were washed with Hanks’s balanced salt solution (0.138 M NaCl, 5.33 mM KCl, 0.338 
mM Na2HPO4, 0.441 mM KH2PO4, 1.26 mM CaCl2, 0.493 mM MgCl2, 0.407 mM MgSO4, 
4.17 mM NaHCO3). Fluorescence was measured on 530 nm as excitation and 590 nm as 
emission wavelength. TMRE fluorescence was normalized to protein content. 
 
Protein extraction and Western blotting 
Cells were lysed with RIPA buffer (1% Nonidet P-40, 1% sodium-deoxycholate, 0,1% SDS, 
0,15 M NaCl, 0,01 M sodium-phosphate, 2 mM EDTA, 50 mM sodium-fluoride and freshly 
added protease inhibitor cocktail (Sigma, 1:100)). Cells were left on ice for several minutes in 
the buffer then were homogenized with a 22-gauge needle. Lysates were cleared by 
centrifugation. Extracts were separated by SDS-PAGE and were blotted as in23. Blots were 
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probed with the following antibodies: SIRT1 (1:1000, Millipore-Upstate, Billerica, MA, 
USA), actin (1:1000, Sigma, St. Louis, USA), PARP-2 (1:1000, PARP-2, Alexis). 
 
Total RNA preparation, Reverse Transcription and RT-qPCR 
Total RNA preparation, Reverse Transcription and RT-qPCR was performed similarly as in 
24
. Total RNA was prepared using TRIzol reagent (Invitrogen) according to manufacturer’s 
instructions. 2 µg of RNA was used for reverse transcription (High Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems, Foster City, CA). Diluted cDNA was used for RT-
qPCR. Expression was normalized to the geometric mean of murine 36B4, 18S and 
cyclophyllin.  
Mitochondrial DNA content was determined in qPCR reactions using total DNA extract of 
cells or tissues as described in 19. Primers are summarized in Supplementary Tables S1 and 
S2. 
 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation was performed similarly as in25. In MOVAS cells chromatin-
bound proteins were fixed on DNA by formaldehyde. Nuclei were prepared and chromatin 
was sonicated in order to split DNA into shorter, ~500 bp fragments. PARP-2 bonded 
chromatin fragments were collected by immunoprecipitation using α-PARP-2 (Alexis, Lausen, 
Switzerland) and α-matrix-metalloproteinase-9 (Santa Cruz, Santa Cruz, CA, USA) 
antibodies. Formaldehyde crosslinking was reversed by heating then DNA fragments were 
purified and amplified using SIRT1 promoter-specific primers by qPCR reaction (primers are 
indicated in the respective section of Supplementary materials). The results were expressed as 
a percentage of input. 
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Statistical analysis 
Statistical significance was determined using Student’s t-test. Error bars represent SEM unless 
stated otherwise.  
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Results  
PARP-2 depletion counteracts vascular dysfunction 
We investigated vascular functions after DOX-treatment in PARP-2+/+ and -/- mice first. 
We did not detect major differences in aortic reactivity between untreated (CTL) PARP-2+/+ 
and -/- mice. In contrast, DOX treatment significantly decreased norepinephrine and 5-
hydroxytryptamine (serotonin)-induced contractility of the vessels in PARP-2+/+ mice while 
PARP-2-/- mice were partially protected (Fig. 1A-B). KCl-induced contraction of aortae from 
PARP-2+/+ mice was reduced upon DOX treatment, whereas the contractile responses of 
aortae from PARP-2-/- mice were unaffected (Fig. 1C). These findings suggested a PARP-2-
dependent deterioration of vascular smooth muscle function after DOX treatment in mice. 
Endothelial function was assessed by the application of acetylcholine. Impaired reactivity 
of aortae to acetylcholine after DOX treatment in both PARP-2+/+ and -/- mice indicated that 
the DOX-induced deterioration of endothelial function was independent of PARP-2 (Fig. 1D). 
Moreover, sodium nitroprusside-induced vasorelaxation was not affected by either DOX 
treatment or by the deletion of PARP-2 (Fig. 1E), suggesting that blunted acetylcholine 
responses were not related to impaired NO reactivity of smooth muscle cells. 
Taken together, our physiological data suggested a role for PARP-2 in DOX-evoked 
vascular dysfunction and implicated smooth muscle as a potential target. This notion was 
further supported by decreased smooth muscle actin immunoreactivity in PARP-2+/+ mice 
after DOX treatment suggesting a loss of smooth muscle cells, which was not the case in 
PARP-2-/- mice (Fig. 1F). Importantly, these data identify smooth muscle dysfunction as a 
novel mechanism of DOX-induced vascular damage. In our following experiments, we 
employed an aortic smooth muscle cell line (MOVAS) to reveal the potential mechanisms for 
PARP-2 involvement in DOX-evoked functional deterioration. 
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PARP activity is not altered upon PARP-2 depletion 
Reactive oxygen species produced by mitochondrial redox cycling of DOX has previously 
been shown to trigger PARP activation and PAR synthesis. Moreover, ablation of PARP-1 
resulted in suppressed PAR synthesis and protection against DOX-evoked cardiovascular 
damage12, 13. Since PARP-2 also possesses poly(ADP-ribose) polymerase activity14 we set out 
to investigate the role of PARP-2 in DOX-evoked PAR synthesis and vascular smooth muscle 
dysfunction. 
We detected free radical production in both aortae and MOVAS cells upon DOX 
treatment (Fig. 2A and 2B). Moreover, free radical production was increased upon PARP-2 
ablation. Enhanced free radical production resulted in DNA strand breakage in both types of 
samples as shown by increased TUNEL staining (Fig. 2C and 2D). However, there was no 
apparent change in TUNEL positivity upon PARP-2 ablation or depletion neither in mice, nor 
in MOVAS cells (Fig. 2C and 2D). The level of DOX-induced PARP activity was not 
different between PARP-2+/+ and -/- mice (Fig. 2E). Similarly, there was no marked difference 
in PARP activation between MOVAS cells in which PARP-2 was silenced by specific shRNA 
(shPARP-2) or its unspecific scrambled version (scPARP-2) (Fig. 2F). These results 
suggested a dominant role for PARP-1 in DOX-evoked PAR formation. PAR was detected 
only in smooth muscle cells suggesting that DOX-evoked endothelial dysfunction is both 
PARP-1 and PARP-2 independent. Cellular NAD+ depletion was also similar in control and 
PARP-2-depleted cells (Fig. 2G) suggesting again a minor, if any role for PARP-2 in this 
process. Taken together, PARP-2 depletion or deletion results in vascular protection without 
affecting DOX-induced overall PARP activity. 
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SIRT1 overexpression counteracts DOX toxicity 
Apparently the protection provided by the depletion of PARP-2 has a different mechanism 
than the one responsible for the protective effect of PARP-1 inhibition. Mitochondrial 
function and structure is deteriorated upon DOX treatment26. Moreover, preservation of 
mitochondrial function is associated with protection against DOX toxicity27-29. These 
observations prompted us to investigate pathways that modulate mitochondrial function. 
SIRT1 is an NAD+-dependent class III deacetylase that promotes mitochondrial biogenesis30-
32
, while PARP-2 has been identified as a repressor of SIRT1 expression19. Danz and 
colleagues have shown that pharmacological activation of SIRT1 by resveratrol enhances 
mitochondrial biogenesis in cardiomyocytes. Thus induction of SIRT1 by PARP-2 depletion 
might be capable of counteracting the free radical-evoked mitochondrial dysfunction that 
occurs upon DOX treatment33. Accordingly, we tested whether increased SIRT1 expression 
might be the key protective mechanism against DOX treatment in PARP-2-/- mice. 
Disruption, or depletion of PARP-2 in aortae or in MOVAS cells (Fig. 3A-B) resulted in 
an increase in SIRT1 mRNA and SIRT1 protein levels (Fig. 3C-D). This increase in SIRT1 
expression was associated with the induction of the SIRT1 promoter (Fig. 3E), which was 
mediated by a decrease in the occupancy of SIRT1 promoter by PARP-2 (Fig. 3F). 
SIRT1 activation enhances mitochondrial oxidative capacity of multiple metabolic 
tissues31. We detected increased mitochondrial DNA content both in the aorta and in MOVAS 
cells upon the deletion or depletion of PARP-2 (Fig. 4A, C). Increased mitochondrial 
biogenesis was further supported by increased expression of genes involved in biological 
oxidation (Foxo1, ATP5g1, ndufa2, ndufb5) in aortae (Fig. 4B). Higher expression of 
oxidative genes was maintained in PARP-2-/- mice even after DOX treatment compared to +/+ 
mice (Fig. 4B). To provide further evidence for the involvement of increased mitochondrial 
activity, mitochondrial membrane potential and oxygen consumption was determined in 
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MOVAS cells upon DOX treatment (Fig. 4D, E). Without DOX treatment scPARP-2 and 
shPARP-2 MOVAS cells displayed similar mitochondrial membrane potential, but PARP-2 
silencing resulted in slightly higher oxygen consumption rate. Oxygen consumption and free 
radical production increased at 7 hours after DOX treatment (Fig. 2B, Fig. 4D) suggesting 
mitochondrial uncoupling and mitochondrial dysfunction. Mitochondrial membrane potential 
in scPARP-2 MOVAS cells increased in line with the increment of DOX concentration 
suggesting mitochondrial hyperpolarization (Fig. 4E). Hyperpolarization of mitochondrial 
membrane has been described as an early event in apoptosis supporting impaired 
mitochondrial biogenesis34. Overall, oxygen consumption was higher in shPARP-2 MOVAS 
cells than in scPARP-2 cells. The difference in oxygen consumption increased upon DOX 
treatment similarly, while mitochondrial hyperpolarization was much lower suggesting milder 
mitochondrial damage (Fig. 4D, E).  
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Discussion 
Doxorubicin toxicity affects both cardiac and vascular functions1. In the vasculature DOX 
treatment has been shown to affect endothelial function9 but no definitive data are available 
for its effect on the vascular smooth muscle and the extracellular matrix4, 5, 10. We have 
affirmed the deterioration of endothelial function in DOX treated animals but it seems to be 
independent from both PARP-2 and PARP-1, at least two days post treatment. Importantly, 
however, early upon DOX administration vascular smooth muscle is also damaged. We have 
shown that the deletion of PARP-2 provided protection against the vascular failure induced by 
DOX. Moreover this protective phenotype was linked to the preservation of vascular smooth 
muscle. PARP-2 depletion did not modulate the DNA breakage – PARP-1 activation – cell 
death pathway. Therefore, it is likely that in PARP-2 does not affect PARP-1 activation that 
may exert its deleterious effects. 
As a possible alternative protective mechanism we have investigated the preservation of 
mitochondrial functions, as it has been shown to protect against DOX toxicity26-29, 33. PARP-2 
depletion has been recently associated with the induction of mitochondrial oxidation through 
the induction of SIRT1 expression19. The link between PARP-2 depletion – SIRT1 activation 
– enhancement of mitochondrial biogenesis was further supported by the fact that SIRT1 
activation has been shown to induce mitochondrial biogenesis in various tissues30-32. Indeed, 
we have detected increased SIRT1 content after PARP-2 ablation both in vivo and in cultured 
aortic smooth muscle cells which was the consequence of the induction of the SIRT1 
promoter. 
The augmented expression and activity of SIRT1 caused enhanced mitochondrial 
biogenesis, which may have contributed to the resistance of PARP-2-/- animals against 
vascular DOX toxicity. It appears that higher level of mitochondrial activity provides an 
advantage for PARP-2-depleted cells over control cells upon oxidative stress-induced 
 by guest on Septem
ber 16, 2011
ca
rdiovascres.oxfordjournals.org
D
ow
nloaded from
 
A
cc
ep
te
d 
M
an
us
cr
ip
t
15 
mitochondrial dysfunction (e.g. DOX treatment). Mitochondrial biogenesis, induced by 
PARP-2 depletion may counterbalance the DOX-induced loss of mitochondrial activity (Fig. 
5.). 
To our best knowledge, this is the first study reporting the protective properties of SIRT1-
induced mitochondrial biogenesis in blood vessels. Indeed, SIRT1 has been shown to act as a 
cardioprotective factor33, 35-38. Pharmacological activation of SIRT1 by resveratrol has been 
demonstrated to induce mitochondrial activity in cardiomyocytes33. However, it must be noted 
that results obtained with resveratrol can not simply be attributed to SIRT activation. as the 
specificity of resveratrol towards SIRT1 is debated39. Moreover, it may act as a free radical 
scavenger40, hence it may eliminate reactive species released by DOX. Therefore, resveratrol 
may interfere with PARP-1 activation by quenching free radicals and hence protect 
mitochondria, or may act on unknown pharmacological targets to confer protection. As Danz 
and colleagues33 have detected a complete loss of free radical production upon resveratrol 
treatment, it cannot be ruled out that resveratrol treatment acted upstream of mitochondrial 
biogenesis induction interfering with PARP-1 activation and provided protection through 
blunting PARP-1-mediated cell death.  
In the heart, SIRT1 can activate other protective mechanisms. As indicated in Fig. 5, 
SIRT1 may deacetylate p53 and induce the expression of Bax family proteins41. SIRT1 may 
also impair PARP-1 activation and the consequent cellular dysfunction through deacetylating 
PARP-138 or by consuming NAD+37. However, we did not observe differences in PARP 
activity or NAD+ consumption in PARP-2 depleted smooth muscle cells or in PARP-2-/- aorta, 
but observed an upregulation of SIRT1 and increased mitochondrial protein expression and 
function. These apparent differences suggest that the mechanism of vascular protection may 
consist of different pathways than the ones observed in the heart. Importantly, however, 
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preservation of mitochondrial function seems to be a key issue in the protection against DOX 
toxicity. 
It is tempting to speculate that SIRT1-mediated induction of mitochondrial biogenesis 
may also have contributed to the protective phenotype of PARP-2 ablation in oxidative stress-
mediated diseases such as colitis16, or cerebral ischaemia15, 17 and could be exploited in other 
oxidative stress-related diseases. This hypothesis calls for the continuation of the development 
of PARP-2-specific inhibitors that may be used in such settings17. 
In summary, here we provide evidence for the protective role of SIRT1 in the vasculature 
and implicate PARP-2 as a new target to limit DOX-induced vascular damage. Furthermore, 
we propose that modulation of the PARP-2 – SIRT1 axis to enhance mitochondrial activity 
may be a new therapeutic pathway to revert mitochondrial hypofunction in the cardiovascular 
system or in other organs. 
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Figure legends 
Figure 1. Genetic deletion of PARP-2 protects against DOX-induced aortic dysfunction 
PARP-2+/+ and -/- mice (3 months of age) were injected with saline (CTL) or with 25 mg/kg 
doxorubicin (DOX) (n= 10 for PARP-2+/+ CTL, n=7 for PARP-2-/- CTL, n=8 for PARP-2+/+ 
DOX and n=8 for PARP-2-/- DOX). Aortae were harvested 2 days post injection. Aortic rings 
were mounted on an isometric contractile force measurement system (A-E) or embedded in 
paraffin (F). Aortic contractile responses (smooth muscle function) were tested by the 
cumulative application of norepinephrine (A), 5-hydroxytryptamine (B) and potassium 
chloride (C) and endothelial function was tested by acetylcholine (D) and smooth muscle NO 
sensitivity by sodium nitroprusside (E). Smooth muscle actin was visualized by 
immunohistochemistry (F). Luminal side is indicated (Lu), scale bar equals 20 µm. 
 
Figure 2. Deletion of PARP-2 does not affect free radical-induced PARP activation or 
NAD+ depletion 
PARP-2+/+ and -/- mice were injected with saline (CTL) or with 25 mg/kg doxorubicin (DOX) 
at 3 months of age (n= 5 for PARP-2+/+ CTL, n=5 for PARP-2-/- CTL, n=5 for PARP-2+/+ 
DOX and n=4 for PARP-2-/- DOX, panels A, C, E). An aortic smooth muscle cell line 
(MOVAS) was also tested (panels B, D, F, G; n=3 parallel measurements). MOVAS cells 
were transduced with a PARP-2-silencing (shPARP-2) or scrambled (scPARP-2) shRNA and 
treated with solvent (CTL), 3 µM doxorubicin (DOX) or with 1 mM H2O2. Measurements 
were performed 2 days post DOX injection (aortae) or 7 hours (MOVAS) after DOX 
treatment. Free radical formation was measured by determining thiobarbituric acid reactive 
species (TBARS) (A) and HE fluorescence (B). DNA breaks were detected using TUNEL 
assay; scale bar represents 20, or 10 µm, respectively (C and D). PAR formation in paraffin 
embedded aortae was assessed with an anti-PAR antibody; scale bar represents 20 µm (E), or 
 by guest on Septem
ber 16, 2011
ca
rdiovascres.oxfordjournals.org
D
ow
nloaded from
 
A
cc
ep
te
d 
M
an
us
cr
ip
t
24 
in MOVAS cells by the PARP enzyme activity assay (F). NAD+ concentrations were 
determined in MOVAS cells using an alcohol dehydrogenase-coupled colorimetric assay (G). 
Lu – lumen, ### indicate statistically significant difference between CTL and DOX/H2O2 
treated samples, at p<0.001, * or *** indicate statistically significant difference between 
PARP-2+/+ mice/scPARP-2 cells and PARP-2-/- mice/shPARP-2 cells at p<0.05 or p<0.001, 
respectively. On panels B, F and G error is represented as SD. 
 
Figure 3. Depletion of PARP-2 induces SIRT1 levels in aortic smooth muscle cells. 
PARP-2+/+ and -/- mice were injected with saline (CTL) or with doxorubicin (DOX) at 3 
months of age (n=7, 5, 5, and 5, respectively), and then aortic samples were collected on day 
2 (panels A, C). An aortic smooth muscle cell line (MOVAS) was also tested (panels B, D, E, 
F). MOVAS cells were transduced with a PARP-2-silencing (shPARP-2) or scrambled 
(scPARP-2) shRNA and treated with solvent (CTL), or doxorubicin (DOX). PARP-2 
expression was determined in aortae by immunohistochemistry, scale bar represents 20 µm 
(A), and in MOVAS cells by Western blotting (B). SIRT1 expression was determined in 
aortae by RT-qPCR (C), while in MOVAS cells by Western blotting (D). The activity of the -
1- -91 portion of the SIRT1 promoter was determined in luciferase assays (E, n=6). PARP-2 
binding to the SIRT1 promoter was determined using ChIP assays (F, n=3). Lu – lumen, * 
and *** indicate statistically significant difference between scPARP-2 cells/PARP-2+/+ mice 
and shPARP-2 cells/PARP-2-/- mice at p<0.05, or p<0.001, respectively. On panels E and F 
error is represented as SD. 
 
Figure 4. PARP-2 regulates mitochondrial function: possible involvement of SIRT1 
PARP-2+/+ and -/- mice (3 months of age) were injected with saline (CTL) or with doxorubicin 
(DOX) (n= 7 for PARP-2+/+ CTL, n=5 for PARP-2-/- CTL, n=5 for PARP-2+/+ DOX and n=7 
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for PARP-2-/- DOX), and then aortic samples were collected on day 2 (panels A, B). An aortic 
smooth muscle cell line (MOVAS) was also tested (panels C, D, E). MOVAS cells (n=3 
parallel measurements) transduced with a PARP-2-silencing (shPARP-2) or scrambled 
(scPARP-2) shRNA were treated with solvent (CTL), or doxorubicin (DOX). (A, C) 
Mitochondrial DNA content was determined by qPCR. (B) Expression of a set of 
mitochondrial genes was determined by RT-qPCR. (D) Oxygen consumption rate was 
measured as described in Materials and Methods (open symbols represent CTL (n=8); filled 
symbols represent DOX (n=8)). (E) Membrane potential was determined using TMRE dye. 
### indicate statistically significant difference between DOX-treated samples and their 
respective controls, at p<0.001; *, *** indicate statistically significant difference between 
PARP-2+/+ mice/scPARP-2 cells and PARP-2-/- mice/shPARP-2 cells at p<0.05, p<0.001, 
respectively. On panels C and D error is presented as SD. 
 
Figure 5. Proposed mechanism for PARP-2-dependent protection against DOX-evoked 
vascular dysfunction  
Doxorubicin treatment evokes vascular dysfunction, which is mediated by an increase in free 
radical formation, resulting in DNA breaks, PARP-1 activation and cellular energetic 
catastrophe. However, doxorubicin-induced toxicity is partially antagonized by PARP-2 
depletion. PARP-2 down-regulation evokes an increase in SIRT1 expression, which results in 
the activation of mitochondrial biogenesis. Elevated mitochondrial function protects aortic 
smooth muscle from doxorubicin-induced toxicity without affecting PARP-1-mediated 
functions. 
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